awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26745686-0E0A5CFC-A360-4A21-8906-67B7E39E60C4
Q26745686-0E0A5CFC-A360-4A21-8906-67B7E39E60C4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26745686-0E0A5CFC-A360-4A21-8906-67B7E39E60C4
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy
P2860
Q26745686-0E0A5CFC-A360-4A21-8906-67B7E39E60C4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26745686-0E0A5CFC-A360-4A21-8906-67B7E39E60C4
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
c20c512b519655a49a9ff0badfcfafadf75e569f
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer